Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: $SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syros Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syros Pharmaceuticals's position in the market.
Syros Pharmaceuticals (SYRS) reported its first-quarter 2024 financial results and provided a corporate update. The company highlighted passing an interim futility analysis in the Phase 3 SELECT-MDS-1 trial, with pivotal CR data expected by mid-Q4 2024. Additionally, the FDA granted Fast Track designation for Tamibarotene in unfit AML. Financially, Syros recorded no revenue compared to $3 million in Q1 2023, and a net loss of $3.7 million, significantly reduced from $23.8 million the previous year. R&D expenses were $24.7 million, down from $28.8 million, while G&A expenses also decreased from $7.4 million to $6.3 million. The company’s cash position was $108.3 million as of March 31, 2024, sufficient to fund operations into Q3 2025.
Syros Pharmaceuticals (SYRS) will participate in two upcoming investor conferences to discuss advancements in the treatment of hematologic malignancies. The company's management will engage in a fireside chat at the JMP Securities 2024 Life Sciences Conference on May 14 and the TD Cowen’s 5th Annual Oncology Innovation Summit on May 29. Interested parties can access webcasts and archived recordings of the events on the Syros website.
Syros Pharmaceuticals (NASDAQ:SYRS) will report its first quarter 2024 financial results on Tuesday, May 14, 2024, with a live conference call and webcast scheduled. The company aims to advance new standards of care for hematologic malignancies.